Overview
What is The Leukemia & Lymphoma Societyinc?
The Leukemia & Lymphoma Societyinc, headquartered in Rye Brook, New York, is a leading nonprofit organization dedicated to advancing research and treatments for blood cancer, including leukemia, lymphoma, Hodgkin's disease, and myeloma. They have been instrumental in funding and accelerating research that has led to the approval of 75% of the nearly 100 new blood cancer treatments over the past five years. Their research efforts span the entire continuum, from basic laboratory science to clinical trials and private-sector drug development alliances. Their mission is to cure blood cancers and improve patients' lives and their families'. They have invested over 1.6 billion dollars in research to date and have seen significant advancements, such as Chimeric Antigen Receptor T cell (CAR T) therapy, which has produced cures for some patients who have exhausted all other options. In fiscal year 2022, they supported research in the US, Canada, and nine other countries with a total research disbursement of approximately 54.6 million dollars. They also introduced Impact Research Grants to address unequal representation of underserved populations in clinical trials, with a goal of increasing trial enrollment among these populations to at least 20%. Additionally, their Therapy Acceleration Program (TAP) has partnered with over 70 biotech companies and academic researchers to extend the therapeutic landscape in blood cancer, leading to three FDA approvals and over 20 active clinical studies.
Official website here: www.lls.org
What are the reviews and ratings of this charity?
Charity Navigator Rating: 97%, Four-Star out of Four Star rating
The Leukemia & Lymphoma Society (LLS) has achieved an impressive 97% rating from Charity Navigator, demonstrating a high level of accountability and financial health. Their strong scores in Impact & Measurement (100%) and Leadership & Adaptability (100%) highlight the organization's effective approach to supporting patients facing blood cancers. The program expense ratio of 74.59% indicates a substantial portion of their revenue is directed toward their programs, reinforcing their commitment to their mission.
User feedback reflects a diverse range of experiences with LLS, showcasing both profound gratitude and dissatisfaction. Many patients and caregivers express appreciation for the organization's comprehensive support, including educational resources, financial assistance, and empathetic guidance during challenging times. Positive testimonials praise specific staff members for their responsiveness and the invaluable information provided, which has significantly impacted the journeys of those dealing with blood cancers.
However, some reviews signal frustrations regarding funding processes and perceived inconsistencies in assistance. One user detailed a lack of support during a critical time, feeling neglected and overwhelmed by bureaucratic hurdles. While these experiences are not representative of all interactions, they underscore the need for LLS to address potential gaps in their service delivery to ensure that all patients feel supported and valued. Overall, LLS demonstrates a strong commitment to making a difference in the lives of those affected by blood cancers, though there remains room for improvement in specific areas.
This AI summary has been generated from information found on Charity Navigator and Great Nonprofits.
Is The Leukemia & Lymphoma Societyinc legitimate?
The Leukemia & Lymphoma Societyinc is a legitimate nonprofit organization registered as a 501(c)(3) entity. The Leukemia & Lymphoma Societyinc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $2,091,645
Professional Fundraising Fees: $5,554,287
Other Salaries and Wages: $88,505,319
For more financial information, click here
Official website here: www.lls.org
What is the mission statement of The Leukemia & Lymphoma Societyinc?
The Leukemia & Lymphoma Societyinc is dedicated to curing leukemia, lymphoma, Hodgkin's disease, and myeloma, and improving the quality of life for patients and their families. They achieve this by funding groundbreaking cancer research and propelling novel treatments through various stages of the drug approval process. Over the last five years, LLS support has contributed to 75% of the almost 100 blood cancer treatment approvals. Their investment in research initiatives, such as precision medicine, immunotherapy, and mutation-linked treatments, is transforming the landscape of cancer care. The society's deliberate and purposeful approach to research has led to the development of lifesaving and less toxic therapies, including CAR T therapy, which has produced cures in patients who have failed all other therapeutic options. The organization's investment in research totals over 1.6 billion dollars and has had significant impact in extending the therapeutic landscape for blood cancer patients. In fiscal year 2022, they supported research in the US, Canada, and 9 other countries. Additionally, LLS has introduced Impact Research Grants to address unequal representation of underserved populations in clinical trials and expand access to state-of-the-art therapies for a broader range of newly diagnosed blood cancer patients.
Official website here: www.lls.org
Who is the CEO of The Leukemia & Lymphoma Societyinc?
Louis J Degennaro is the President & of The Leukemia & Lymphoma Societyinc.
Official website here: www.lls.org
What is the revenue of The Leukemia & Lymphoma Societyinc?
The Leukemia & Lymphoma Societyinc's revenue in 2022 was $426,997,204.
Official website here: www.lls.org
Who are the executives of The Leukemia & Lymphoma Societyinc and what are their salaries?
The average compensation at The Leukemia & Lymphoma Societyinc during 2022 was $76,973. There are 1177 employees at The Leukemia & Lymphoma Societyinc.
Here are 28 key members and their salaries:
- Compensation: $1,011,186
- Related: $0
- Other: $51,204
- Compensation: $609,795
- Related: $0
- Other: $43,790
- Compensation: $593,456
- Related: $0
- Other: $24,936
- Compensation: $482,778
- Related: $0
- Other: $55,947
- Compensation: $493,477
- Related: $0
- Other: $19,326
- Compensation: $439,953
- Related: $0
- Other: $65,803
- Compensation: $437,669
- Related: $0
- Other: $31,401
- Compensation: $424,061
- Related: $0
- Other: $39,696
- Compensation: $384,232
- Related: $0
- Other: $66,083
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Official website here: www.lls.org
Where can I find the form 990 for The Leukemia & Lymphoma Societyinc?
The Leukemia & Lymphoma Societyinc's most recent form 990 was submitted in 2022 and can be accessed here.
Official website here: www.lls.org
Learn more at the official website: www.lls.org
Mission Statement of The Leukemia & Lymphoma Societyinc
The Leukemia & Lymphoma Societyinc (LLS) is a leading organization in the mission to cure leukemia, lymphoma, Hodgkin's disease, and myeloma, as well as improving the quality of life for patients and their families. LLS's relentless pursuit of advancements in cancer research propels groundbreaking treatments through all phases of the drug approval process. With a significant investment of over 1.6 billion dollars towards research, LLS has been instrumental in the approval of 75% of blood cancer treatments over the last five years.
LLS's impact reaches beyond the United States, with research funding distributed in 9 other countries. The organization's commitment to finding and supporting research most likely to benefit patients as soon as possible is evident in their sustained investments over several decades. One of the most notable successes includes their early investment in Chimeric Antigen Receptor T cell (CAR T) therapy in 1990, which has resulted in 12 FDA-approved CAR T therapies for acute B-cell leukemia, non-Hodgkin lymphoma, and multiple myeloma. These therapies have produced cures for patients who have exhausted all other therapeutic options.
In addition to research, LLS also aims to increase clinical trial enrollment among underrepresented populations. The organization's Impact Research Grants, a five-year investment of 3.75 million dollars, aims to expand clinical trial access to local community-based hospitals and clinics. This initiative will help increase trial enrollment among racial and ethnic minorities, rural residents, and individuals with low income, ensuring that a broader range of newly diagnosed blood cancer patients have access to state-of-the-art therapies.
In summary, The Leukemia & Lymphoma Societyinc is an influential organization dedicated to curing blood cancers and improving patients' lives. With a rich history of groundbreaking research and a commitment to increasing access to clinical trials, LLS is at the forefront of advancing treatments for leukemia, lymphoma, Hodgkin's disease, and myeloma.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
The Leukemia & Lymphoma Society Inc. (LLS) is dedicated to curing leukemia, lymphoma, Hodgkin's disease, and myeloma while enhancing the quality of life for patients and their families. Its profound impact is evident through a multifaceted approach to cancer research, patient care, and community support.
LLS is a leading force in advancing groundbreaking treatments for blood cancers. By investing over $1.6 billion in research, LLS has propelled 75% of nearly 100 blood cancer treatment approvals in the last five years. Their focus on innovative areas like precision medicine and immunotherapy has not only expanded the therapeutic landscape but also provided hope to patients facing dire diagnoses. A notable example is the pivotal support for CAR T therapy, which has led to numerous FDA approvals and remarkable outcomes, including potential cures for patients who have exhausted other treatment options.
The organization also emphasizes equitable access to clinical trials through initiatives like the IMPACT Grants, designed to enhance trial enrollment among underserved populations. This effort aims to ensure that advancements in treatment reach a diverse patient base, fostering inclusivity in cancer research and care.
LLS has also pioneered significant clinical trials, such as the BEAT AML Master Trial and the PEDAL Master Trial, which utilize cutting-edge genomic and biomarker approaches to tailor therapies for acute myeloid leukemia and pediatric acute leukemia, respectively. These trials represent a shift toward personalized medicine, reflecting LLS’s commitment to improving treatment outcomes.
Moreover, LLS has adapted to challenges presented by the COVID-19 pandemic by launching the National Patient Registry, gathering critical data on vaccine safety and efficacy for blood cancer patients, thereby aiding informed decision-making in healthcare.
With a holistic approach that encompasses rigorous research, innovative trial programs, and a steadfast commitment to patient advocacy, LLS is significantly advancing the fight against blood cancers, making a meaningful difference in the lives of thousands of patients and their families.
This information is meant to be a general summary of The Leukemia & Lymphoma Societyinc. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Investment Income: $6,919,696
- Program Service Revenue: $11,597,762
- Gross Receipts: $675,392,108
Assets and Liabilities:
- Total Assets: $693,676,206
- Total Liabilities: $321,732,744
- Net Assets: $371,943,462
Want to help this charity, for free? You can click here to learn more about Give Freely
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
SERVICE REVENUE
Revenue
$11,597,762
Organization Details
Founding Year
1949
Phone
(914) 949-5213Principal Officer
Louis J Degennaro
Main Address
3 INTERNATIONAL DRIVE SUITE 200, RYE BROOK, NY, 10573
Website
www.lls.orgNTEE Category
Code: G300 - Disease
If you are a representative of The Leukemia & Lymphoma Societyinc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.